Where is biological therapy going?

Arthritis Research

Volumn 2, Issue 5, 2000, Pages 337-341

  Schulze Koops, H ^a   Kalden, J R ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Biologicals; Cytokines; Monoclonal antibodies; Rheumatoid arthritis; Treatment

Indexed keywords

CD4 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1 ANTIBODY; MONOCLONAL ANTIBODY; OKT 4; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CELL FUNCTION; CHRONIC INFLAMMATION; CYTOLOGY; EFFECTOR CELL; EXPECTATION; FUTUROLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTENSIVE CARE; MOLECULAR BIOLOGY; NOTE; PATHOGENESIS; RHEUMATOID ARTHRITIS; SYMPTOM; T LYMPHOCYTE ACTIVATION; TARGET CELL; TH1 CELL; TH2 CELL;

AUTOIMMUNE DISEASES; BIOLOGICAL THERAPY; HUMANS;

EID: 0034469911     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar108     Document Type: Note

References (33)

1. Anti-CD4 and other antibodies to cell surface antigens for therapy
2. Immunological treatment of autoimmune diseases
3. What we have learned from trials of immunomodulatory agents in RA: Future directions
4. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4
5. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker
6. Immunotherapy of the nonobese diabetic mouse: Treatment with an antibody to T-helper lymphocytes
7. Reprogramming the immune system for tolerance with monoclonal antibodies
8. Manipulation of T-cell responses with monoclonal antibodies
9. Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4
10. Adhesion receptors of the immune system
11. Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes
12. The role of CD11/CD18 in adhesion and transendothelial migration of T cells: Analysis utilizing CD18 deficient T cell clones
13. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1
14. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody
15. The role of cytokines in the pathogenesis of rheumatoid arthritis
16. The immunopathogenesis of rheumatoid arthritis: The role of cytokines in chronic inflammation
17. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium
18. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
19. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis
20. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
21. Neutralization of TNF by lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for three months: Results of a European phase II trial
22. Anti-cytokine therapy for rheumatoid arthritis
23. Development of anti-ds DNA antibodies in patients with rheumatoid arthritis treated with a chimeric monoclonal antibody to TNF alpha
24. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
25. Manipulation of the Th1/Th2 cell balance: A approach to treat human autoimmune diseases?
26. TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease
27. + T cell subset that inhibits this autoimmune potential
28. Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity: Relative roles of interleukin (IL)-4 and IL-10
29. Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis: Modulation by treatment with anti-ICAM-1 correlates with clinical benefit
30. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease
31. Altered memory T cell differentiation in patients with early rheumatoid arthritis
32. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology
33. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein